Skip to main content
Livermore
Livermore
ZHEN

Yale University

SEC CIK
0000938582
Latest filing
Nov 14, 2025

The latest 13F from Yale University covers Q3 2025 (filed Nov 14, 2025): 4 long positions worth $2.05M. The top 10 holdings make up 100.0% of the portfolio, and the largest is iShares Tr Core S&P TTL STK at 44.4%. Livermore has 26 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q3 2025

Share counts compared with Q2 2025: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
2
Est. +$1.13M
Added
1
Est. +$14.0K
Reduced
0
Sold out
0

Top 5 holdings

Share of this quarter's portfolio value

  1. iShares Tr Core S&P TTL STK046428715
    44.4%$911.8K
  2. VERAVera Therapeutics, Inc.
    32.3%$662.9KHistory
  3. DOOBRP Inc.
    22.7%$466.4KHistory
  4. REIRing Energy, Inc.
    0.7%$13.8KHistory

Biggest buys

New and added positions, by estimated amount bought

  1. VERAVera Therapeutics, Inc.
    +$662.9KNewHistory
  2. DOOBRP Inc.
    +$466.4KNewHistory
  3. iShares Tr Core S&P TTL STK046428715
    +$14.0KAdded

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. VERAVera Therapeutics, Inc.
    +32.26 pp0.0% → 32.3%History
  2. DOOBRP Inc.
    +22.70 pp0.0% → 22.7%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

None this quarter.

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

None this quarter.

Metrics

13F metrics for Q3 2025, computed only from the numbers in the filings. Definitions below.

Portfolio value
$2.05M
+$1.21M (+143.9%) vs. prior quarter
Positions
4
+2 vs. prior quarter
Top 10 concentration
100.0%
Top 10 as share of value
Turnover
0.0%
Q3 2025, one quarter
Average holding period
1.9 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

19 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $845.0M (Q3 2021)

Q1 2021: $46.2MQ2 2021: $291.7MQ3 2021: $845.0MQ4 2021: $530.2MQ1 2022: $530.3MQ2 2022: $14.8MQ3 2022: $18.7MQ4 2022: $37.3MQ1 2023: $45.9MQ2 2023: $128.9MQ3 2023: $102.2MQ4 2023: $112.9MQ1 2024: $40.0MQ2 2024: $3.48MQ3 2024: $2.43MQ4 2024: $815.3KQ1 2025: $766.6KQ2 2025: $842.4KQ3 2025: $2.05M
Q1 2021Q3 2025
13F filings of Yale University by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q3 2025Nov 14, 20254$2.05MiShares Tr Core S&P TTL STKVERADOOvs. Q2 2025SEC
Q2 2025Aug 14, 20252$842.4KiShares Tr Core S&P TTL STKREIvs. Q1 2025SEC
Q1 2025May 15, 20252$766.6KiShares Tr Core S&P TTL STKREIvs. Q4 2024SEC
Q4 2024Feb 14, 20253$815.3KiShares TrREIALURvs. Q3 2024SEC
Q3 2024Feb 14, 2025Amended3$2.43MRNACiShares TrALURvs. Q2 2024SECSEC
Q2 2024Feb 14, 2025Amended3$3.48MRNACiShares TrALURvs. Q1 2024SECSECSEC
Q1 2024Feb 14, 2025Amended6$40.0MVanguard Ftse Emerging Markets ETFCOINDOOvs. Q4 2023SECSEC
Q4 2023Feb 15, 20247$112.9MACIVanguard Ftse Emerging Markets ETFARVNvs. Q3 2023SEC
Q3 2023Nov 14, 20234$102.2MACIVanguard Ftse Emerging Markets ETFiShares Trvs. Q2 2023SEC
Q2 2023Aug 11, 20234$128.9MACISGENVanguard Ftse Emerging Markets ETFvs. Q1 2023SEC
Q1 2023May 15, 20234$45.9MACIVanguard Ftse Emerging Markets ETFiShares Trvs. Q4 2022SEC
Q4 2022Mar 22, 2023Amended4$37.3MPRCTVanguard Ftse Emerging Markets ETFiShares Trvs. Q3 2022SECSEC
Q3 2022Mar 22, 2023Amended5$18.7MVanguard Ftse Emerging Markets ETFPRCTiShares Tr Core S&P TTL STKvs. Q2 2022SECSEC
Q2 2022Aug 12, 20222$14.8MVanguard Ftse Emerging Markets ETFiShares Trvs. Q1 2022SEC
Q1 2022May 13, 20228$530.3MVanguard Ftse Emerging Markets ETFVanguard Intl Equity Index FiShares Incvs. Q4 2021SEC
Q4 2021Feb 14, 202212$530.2MVanguard Ftse Emerging Markets ETFASANARvs. Q3 2021SEC
Q3 2021Nov 22, 2021Amended12$845.0MVanguard Ftse Emerging Markets ETFEQTSPYvs. Q2 2021SEC
Q2 2021Aug 13, 202116$291.7MVanguard Ftse Developed Markets ETFSPYASANvs. Q1 2021SEC
Q1 2021May 14, 20219$46.2MiShares TrRBLXiShares MSCI Eafe ETF–SEC